Exhibit 99.1






Urologix Reports

Fiscal 2011 Fourth Quarter & Year-End Results


Revenue of $2.9 million, for the fourth quarter and $12.6 million for fiscal year 2011.
A net loss of $1.3 million, or $0.09 per diluted share in the fourth quarter and $3.7 million or $0.26 per diluted share for fiscal year 2011.
New Vice President of Sales and Marketing joins Urologix.


MINNEAPOLIS — August 23, 2011 — Urologix®, Inc. (NASDAQ:ULGX), a medical device company focused on developing, manufacturing and marketing Cooled ThermoTherapy™ treatment catheters that provide a durable and effective procedure delivered in the comfort of a urologist’s office for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for its fourth fiscal quarter and fiscal year 2011 ended June 30, 2011.


Fourth quarter fiscal year 2011 revenue totaled $2.9 million, down 11% year-over-year and down 2% sequentially. The decline in revenue on a year-over-year basis was driven by reduced order volumes in all distribution channels: direct, mobile and third party mobile. The sequential decline in revenue was primarily due to lower revenue from our third-party mobile channel.


Fourth quarter fiscal year 2011 revenue was comprised of sales to direct accounts, Urologix mobile service and third-party mobile service, representing 40%, 46% and 12%, respectively, in the period. This compares to a revenue mix of 36%, 47% and 14%, respectively, in the Company’s third quarter of fiscal year 2011.


Gross profit for the fourth quarter of fiscal year 2011 of $1.3 million, or 43% of revenue, declined 11 percentage points year-over-year driven by the allocation of fixed manufacturing costs over lower production volume in the period as well as an additional $158,000 out-of-period expense related to an adjustment to correct over-capitalized manufacturing variances that had accumulated during the previous three quarters. Total operating expense of $2.6 million increased 5% year-over-year driven primarily by higher investments in research and development compared to the fourth quarter of fiscal year 2010.


For the fourth quarter of fiscal year 2011, Urologix reported a net loss of $1.3 million, or $0.09 per diluted share, compared to a net loss of $622,000, or $0.04 per diluted share, in the fourth quarter of fiscal year 2010.


The Company’s cash utilization in the fourth fiscal quarter ended June 30, 2011 was $729,000 compared to cash utilization of $62,000 in the same period last year. As of June 30, 2011, the Company’s cash balance was $3.1 million with no debt obligations outstanding.


“The fourth quarter was challenging for Urologix as the economy continues to pressure elective procedures in urology practices across the country,” stated Stryker Warren jr, CEO. “Despite these challenges, I believe that our competitive position is improving and fueled by recent strategic initiatives. Our patient education programs continue to see early success in raising awareness among the large and growing population of chronic medical therapy BPH patients. Partnering with urologists to introduce these patients to Urologix’s CTT as a safe, effective and durable non-surgical treatment alternative to prescription drugs remains a key focus for our sales teams. The recent addition of Lisa Ackermann as the new Vice President of Sales and Marketing will support our efforts as our team benefits from Lisa’s experience in leading medical device sales organizations.”


For the fiscal year 2011 period ended June 30, 2011, revenue totaled $12.6 million, a decrease of 15% compared to revenue of $14.8 million in fiscal year 2010. Fiscal year 2011 revenue performance was impacted by lower order volumes in all three sales channels and the revenue benefit from the temporary market withdrawal of a competitive product in the prior fiscal year period.




Gross profit for fiscal year 2011 of $6.5 million, or 52% of revenue, declined 3.5 percentage points year-over-year driven by the higher manufacturing expense per unit due to the lower production volume. Total operating expense of $10.3 million declined 2% year-over-year driven by tightly managed variable expenses which allowed the Company to continue to invest in research and development in 2011. The $2.2 million in research and development expense in fiscal year 2011 represented a 22% increase year-over-year.


The Company reported a net loss of $3.7 million, or $0.26 per diluted share, for fiscal year 2011, compared to a net loss of $2.2 million, or $0.15 per diluted share, in the prior fiscal year period.


Earnings Call Information


Urologix will host a conference call with the financial community to discuss fiscal 2011 fourth quarter and full year results on Tuesday, August 23, 2011 at 4:00 p.m. Central Daylight Time. To listen to the call, please dial 1-800-435-1398 and enter the Participant Passcode 73391076 at least 10 minutes prior to the call. A live webcast of the call will be available through the investor relations section of the Company’s website at www.urologix.com and available for replay approximately two hours after the completion of the call.


About Urologix


Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix’ products include the CoolWave® , Targis® and Prostatron® control units and the CTC Advance™, Targis® and Prostaprobe® catheter families. All of Urologix’ products utilize Cooled ThermoTherapy™ - targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.


Forward Looking Statements


This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. Such forward looking statements include, for example, statements about the effectiveness of the Company’s sales and marketing strategies, the Company’s future revenue and operating performance, or about the development and marketing of new products. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2010 and other documents filed with the Securities and Exchange Commission.


Contact: Brian J. Smrdel, Chief Financial Officer, (763) 475-7696





- Financials Follow -





Urologix, Inc.

Statements of Operations

(Unaudited, in thousands, except per share data)


    Three Months Ended
June 30,
    Twelve Months Ended
June 30,
    2011     2010     2011     2010  
Sales   $ 2,916     $ 3,260     $ 12,571     $ 14,771  
Cost of goods sold     1,663       1,503       6,030       6,569  
Gross profit     1,253       1,757       6,541       8,202  
Costs and expenses:                                
Selling, general and administrative     1,987       1,940       8,029       8,625  
Research and development     583       513       2,238       1,834  
Total costs and expenses     2,570       2,453       10,267       10,459  
Operating loss     (1,317 )     (696 )     (3,726 )     (2,257 )
Interest income                 1        
Loss before income taxes     (1,317 )     (696 )     (3,725 )     (2,257 )
Income tax expense (benefit)     13       (74 )     8       (88 )
Net loss   $ (1,330 )   $ (622 )   $ (3,733 )   $ (2,169 )
Net loss per common share--basic   $ (0.09 )   $ (0.04 )   $ (0.26 )   $ (0.15 )
Net loss per common share--diluted   $ (0.09 )   $ (0.04 )   $ (0.26 )   $ (0.15 )
Weighted average number of common shares outstanding--basic     14,588       14,522       14,556       14,508  
Weighted average number of common shares outstanding--diluted     14,588       14,522       14,556       14,508  



Urologix, Inc.

Balance Sheets

(Unaudited, in thousands)


    June 30, 2011     June 30, 2010  
Current assets:                
Cash and cash equivalents   $ 3,061     $ 5,702  
Accounts receivable, net     1,358       1,378  
Inventories     1,127       1,498  
Prepaids and other current assets     249       139  
Total current assets     5,795       8,717  
Property and equipment:                
Property and equipment     11,691       11,669  
Less accumulated depreciation     (10,830 )     (10,655 )
Property and equipment, net     861       1,014  
Identifiable intangible assets, net     102       123  
Other assets     5       349  
Total assets   $ 6,763     $ 10,203  
Current liabilities:                
Accounts payable   $ 741     $ 434  
Accrued compensation     454       875  
Deferred income     21       169  
Other accrued expenses     541       519  
Total current liabilities     1,757       1,997  
Deferred income     9        
Other accrued liabilities     151        
Total liabilities     1,917       1,997  
Shareholders’ equity:                
Common stock     144       144  
Additional paid-in capital     114,733       114,360  
Accumulated deficit     (110,031 )     (106,298 )
Total shareholders’ equity     4,846       8,206  
Total liabilities and shareholders’ equity   $ 6,763     $ 10,203  







Urologix, Inc.

Condensed Statements of Cash Flows

(Unaudited, in thousands)


    Twelve Months Ended
June 30,
    2011     2010  
Operating Activities:                
Net loss   $ (3,733 )   $ (2,169 )
Adjustments to reconcile net loss to net cash used for operating activities:                
Depreciation and amortization     565       793  
Employee stock-based compensation expense     369       440  
Provision for bad debts     (46 )     47  
Loss on disposal of assets     12       2  
Change in operating items:                
Accounts receivable     66       80  
Inventories     243       (387 )
Prepaids and other assets     234       158  
Accounts payable     307       (28 )
Accrued expenses and deferred income     (387 )     (191 )
Net cash used for operating activities     (2,370 )     (1,255 )
Investing Activities:                
Purchase of property and equipment     (272 )     (81 )
Purchases of intellectual property     (3 )     (4 )
Net cash used for investing activities     (275 )     (85 )
Financing Activities:                
Proceeds from stock option exercises     4       10  
Net cash provided by financing activities     4       10  
Net decrease in cash and cash equivalents     (2,641 )     (1,330 )
Cash and cash equivalents:                
Beginning of period     5,702       7,032  
End of period   $ 3,061     $ 5,702  
Supplemental cash-flow information                
Income taxes paid during the period   $ 17     $ 13  
Net amount of inventory transferred to property and equipment   $ 128     $ 296  





The following information was filed by Urologix Inc (ULGX) on Wednesday, August 24, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Urologix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Urologix Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account